GET IN TOUCH

ABOUT GREYLEDGE TECHNOLOGIES

Greyledge Technologies was established by Dr. David C. Karli to meet emerging physician and patient demands to facilitate and utilize mechanisms of natural healing to augment and/or support treatment of disease. Dr. Karli also recognized the deficiency in product quality in the growing field and that Physicians didn’t know exactly what they were putting into their patients. In order to meet these first initiative, Greyledge has developed novel, manual laboratory-based methods to process autologous whole blood and bone marrow tissues to produce biologic preparations that are quality and quantity controlled to create a better product and higher level of research and development to advance the field of cellular therapies.

Each of our biologic preparations is carefully analyzed prior to the point at which a physician returns it to the patient. This way, we ensure quality, safety and effectiveness and to meet physician-specified compositions. Greyledge’s approach is flexible, allowing physicians to optimize their practice of medicine through maintaining the highest standards in preparing, analyzing, applying and learning from
autologous PRP and BMC preparations.

If you’re a patient looking for the optimal way to meet your needs, or if you’re a physician looking to integrate Regenerative Medicine seamlessly into your practice, now is the time to reach out to Greyledge. If you’re ready, we’re ready.

Greyledge History Timeline

2003

Dr. Karli Joined The Steadman Clinic

2010

Greyledge Technologies Founded

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

2012

Second Lab Location Started

2013

Website Launched

Published With Mishra A, Et Al. (2014) “Efficacy”

2014

US Patent #9,164,079 Issued

2015

2016

Decision To Launch Nationwide Scale-Up Of Greyledge Technologies

2019

Greyledge expands into multiple States

Executive Team

David C. Karli, MD MBA

Founder, Chief Executive Officer, Board of Directors

Zoe Karli

President, Board of Directors

Jim Johnston

Chief of Corporate Development, Board of Directors

Mark D. Kitchen

VP of Operations

Connor Callen

Director of Data Systems and Analytics

Our Mission

Our mission is to leverage scientific advancements in creating and innovating quality controlled autologous biologic preparations, which enable physicians to optimize the practice of Regenerative Medicine. Greyledge Technologies has created a technology platform that allows physicians the opportunity to integrate autologous PRP and BMC biologic preparations into their practice using a meticulously controlled cell processing facility, coupled with fully documented and validated sample analysis with every product produced.

Our Mission: Our mission is to leverage scientific advancements in creating and innovating quality controlled autologous biologic preparations, which enable physicians to optimize the practice of Regenerative Medicine. Greyledge Technologies has created a technology platform that allows physicians the opportunity to integrate autologous PRP and BMC biologic preparations into their practice using a meticulously controlled cell processing facility, coupled with fully documented and validated sample analysis with every product produced.

ABOUT GREYLEDGE TECHNOLOGIES

Greyledge History Timeline